Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death

Journal Article · Mon Jan 15 04:00:00 EST 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2017.08.042· OSTI ID:23100739

Pickles, Tom ^[1]; Tyldesley, Scott ^[1]; Hamm, Jeremy ^[2]; Virani, Sean A. ^[3]; Morris, W. James; Keyes, Mira ^[1]

---

1. Radiation Program, BC Cancer Agency, Vancouver, British Columbia (Canada)
2. Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver, British Columbia (Canada)
3. Division of Cardiology, University of British Columbia, Vancouver, British Columbia (Canada)

To determine whether the use of 6 months' adjuvant androgen deprivation therapy (ADT) combined with brachytherapy for intermediate-risk (IR) and low-risk (LR) prostate cancer is associated with an increased risk of cardiovascular death.

• OSTI ID: 23100739
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 100; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANDROGENS
BRACHYTHERAPY
DEATH
HAZARDS
NEOPLASMS
PROSTATE